Kimia Biosciences Ltd (KIMIABL) — shareholding pattern, promoter holding, financials and share price
About Kimia Biosciences Ltd (KIMIABL)
Kimia Biosciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as KIMIABL and on the BSE under scrip code 530313. Its ISIN is INE285U01025.
Incorporated in 1993, Kimia Biosciences Ltd is in the business of manufacturing and sale pharmaceutical products [1]
Kimia Bio-sciences Limited, formerly known as Laurel Organics Limited, focuses on manufacturing bulk drugs and APIs at its plant in Gurgaon, Haryana.
The company faced financial difficulties and was declared a sick unit during 1998-99, but later recovered and moved out of the BIFR purview by 2005.
Listed peers in Pharmaceuticals: Panchsheel Organics Ltd, Auro Laboratories Ltd, Quest Laboratories Ltd, Natural Capsules Ltd, Alpa Laboratories Ltd, Smruthi Organics Ltd.
Valuation & Returns
10 Jul 2026At ₹31.03 a share on 10 Jul 2026, Kimia Biosciences Ltd (KIMIABL) was valued at a price-to-earnings ratio of 19.76x against an industry P/E of 36.41x and a price-to-book of 14.73x on a book value of ₹2.11 per share as of Mar 2025. Solomo computes return on equity of 74.55% and return on capital employed of 27.84% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 19.76x
- Industry P/E
- 36.41x
- P/B
- 14.73x
- EPS (TTM)
- ₹1.57
- Book value / share
- ₹2.11
- ROE
- 74.55%
- ROCE
- 27.84%
- ROA
- 6.68%
- Debt / equity
- 3.31x
- Dividend yield
- 0%
- EBITDA margin
- 13.82%
- 52-week range
- ₹23.2 – ₹73.08
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Kimia Biosciences Ltd (KIMIABL) reported revenue of ₹115 crore, net profit of ₹7 crore and earnings per share of ₹1.57. That compares with revenue of ₹119 crore and net profit of ₹10 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹27.2 crore and net profit ₹0.37 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 125 | 129 | 105 | 119 | 115 |
| Net profit (₹ cr) | -4 | -9 | -5 | 10 | 7 |
| EPS (₹) | -0.78 | -1.98 | -1.12 | 2.03 | 1.57 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 104.26% | 2.27% | -1.62% | 13.39% |
| Profit growth | - | 47.41% | - | 280.98% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 74.94% of Kimia Biosciences Ltd (KIMIABL) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.38%. Market capitalisation was ₹147 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Anish Kumar Aggarwal 4.33%, Manish Gupta 4.25%, Roma Mittal 4.11%, Rahul Agrawal 3.33%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 74.94% | - | - | 0.38% | 25.06% |
| Mar 2026 | 74.94% | - | - | 0.38% | 25.06% |
| Dec 2025 | 74.94% | - | - | 0.38% | 25.06% |
| Sep 2025 | 74.94% | - | - | 0.38% | 25.06% |
| Jun 2025 | 74.94% | - | - | 0.38% | 25.06% |
| Mar 2025 | 74.94% | - | - | 0.38% | 25.06% |
| Dec 2024 | 74.94% | - | - | 0.38% | 25.06% |
| Sep 2024 | 74.94% | - | - | 0.38% | 25.06% |